G1 Therapeutics, Inc.
G1 Therapeutics, Inc. (GTHX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
gthx · stock forecast · 11 analysts (3M) · FMP · updated Apr 25, 2025
Analyst Rating & Consensus
Based on 11 Wall Street analysts in the past 3 months
Buy
11 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$6.00
Consensus
$4.50
-37.1% upside
Low
$3.00
Median: $4.5 · Last Close: $7.15
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$4.50
-37.1% upside
High Target
$6
-16.1%
Low Target
$3
-58.0%
Current Price
$7.15
as of today
Based on analyst price targets, the GTHX stock price prediction for the next 12 months ranges from $3 to $6. The consensus GTHX price forecast of $4.50 implies -37.1% upside from the current price of $7.15.
Short-Term Price Prediction
BullAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $7.16 | ↑ 0.12% |
1-day model range: $7.16–$7.16. Peak: $7.16 (+0.12%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · GTHX · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-08-07 | Needham | Downgrade ↓ | Buy→Hold |
| 2024-06-25 | Needham | Maintains | Buy→Buy |
| 2024-06-25 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-06-13 | Needham | Maintains | Buy→Buy |
| 2024-05-28 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-05-28 | Needham | Maintains | Buy→Buy |
| 2024-05-22 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-05-22 | Needham | Maintains | Buy→Buy |
| 2024-05-02 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-05-01 | Needham | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on G1 Therapeutics, Inc. (GTHX) stock. Of the recent 89 rating actions, 4 were upgrades and 10 were downgrades. 11 analysts currently cover GTHX.
Analyst Recommendation Trends
GTHX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$69M
↓ 89.8% YoY
Revenue Next Year
$89M
↑ 29.9% YoY
EPS This Year
$-0.45
EPS Next Year
$0.14
↓ 131.4% YoY
EPS ForecastReported vs Estimated
Analysts forecast GTHX EPS of $-0.45 for the current fiscal year, based on estimates from 2 analysts. The GTHX revenue forecast is $69M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The GTHX stock forecast is supported by two independent data sources: analyst consensus ratings from 11 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus GTHX price target is $4.50 (-37.1% upside), with an analyst consensus of Buy.
The GTHX short-term stock prediction for tomorrow is $7.16 (+0.12%).
G1 Therapeutics, Inc. trades on NASDAQ under the ticker GTHX. The GTHX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 82% of covering analysts.
Frequently asked questions
GTHX forecast · 8 questionsAccording to 11 Wall Street analysts, the average 12-month GTHX price target is $4.50, with a high forecast of $6.00 and a low of $3.00. The median price target is shown in the chart above when available. This implies -37.1% potential upside from the current price of $7.15.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.